Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism

Summary

Hyperhomocysteinemia is a risk factor of venous thromboembolism. The risk of recurrence in patients with hyperhomocysteinemia is unknown, and the optimal therapy for these patients after acute venous thromboembolism is uncertain.

In a multicenter study, 264 patients with an objectively documented single episode of idiopathic venous thromboembolism were prospectively followed after discontinuation of oral anticoagulants. Patients were classified as hyperhomocysteinemic if their homocysteine levels exceeded the 95th percentile of the controls. The outcome events studied were objectively confirmed deep-vein thrombosis and/or pulmonary embolism.

Homocysteine levels were elevated in 66 patients (25%) and normal in 198 patients (75%). Recurrent venous thromboembolism occurred in 12 of 66 patients with hyperhomocysteinemia (18.2%) and in 16 of 198 patients without hyperhomocysteinemia (8.1%). The cumulative probability of recurrence 24 months after discontinuation of oral anticoagulants was 19.2 percent (95 percent confidence interval 8.7-27) in patients with hyperhomocysteinemia and was 6.3 percent (95 percent confidence interval 2.4-10.1; p = 0.001) in those without hyperhomocysteinemia. The relative risk of recurrent thrombosis was higher in patients with hyperhomocysteinemia [RR 2.7 (1.3-5.8), p = 0.009].

Patients with hyperhomocysteinemia are at high risk of recurrent venous thromboembolism. The high prevalence of hyperhomocysteinemia in thrombosis patients together with the increased risk of recurrence warrants extended patient screening. The impact on the risk of recurrence of prolonged anticoagulation, supplementation of folate and vitamin B₁₂, or both have to be investigated.

• References

• 1 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan A, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis.. Ann Intern Med 1996; 125: 1-7.
• 2 Nordström M, Lindblad B, Bergqvist D, Kjellström TA. A prospective study of the incidence of deep vein thrombosis with a defined urban population.. J Intern Med 1992; 232: 155-60.
• 3 Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study.. Arch Intern Med 1991; 151: 933-8.
• 4 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome.. N Engl J Med 1995; 332: 993-7.
• 5 Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg⁵⁰⁶→Gln mutation in the gene for factor V (factor V Leiden).. N Engl J Med 1997; 336: 399-403.
• 6 Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.. Thromb Haemost 1997; 77: 624-8.
• 7 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.. Circulation 1995; 92: 2800-2.
• 8 Brattström L, Tengborn L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism.. Haemostasis 1991; 21: 51-7.
• 9 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.. Arterioscler Thromb 1994; 14: 1080-3.
• 10 Fermo I, D’Angelo SV, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.. Ann Intern Med 1995; 123: 747-53.
• 11 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.. N Engl J Med 1996; 334: 759-62.
• 12 Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis – a case control study.. Thromb Haemost 1996; 76: 883-6.
• 13 den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-5.
• 14 The PIOPED Investigators.. Value of the ventilation/perfusion scan in acute pulmonary embolism.. JAMA 1990; 263: 2753-9.
• 15 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C.. Nature 1994; 369: 64-7.
• 16 Pabinger I, Brücker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K. Hereditary deficiency of antithrombin III, protein C, and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening.. Blood Coagul Fibrinolysis 1992; 3: 547-53.
• 17 Brandt JT, Triplett DA, Alving B. Scharrer I on the behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.. Criteria for the daignosis of lupus anticoagulants: an update.. Thromb Haemost 1995; 74: 1185-90.
• 18 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data.. John Wiley and Sons,; 1980
• 19 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.. J Am Stat Assoc 1958; 53: 457-81.
• 20 Koeleman BP, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.. Blood 1994; 84: 1031-5.
• 21 Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to ac tivated protein C as an additional genetic risk factor in hereditary deficiency of protein S.. Blood 1995; 85: 3518-23.
• 22 van Boven HH, Reitsma PH, Rosendaal FR, Baiston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.. Thromb Haemost 1996; 75: 417-21.
• 23 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K, Hjorth M, Linder O, Boberg J. and the Duration of Anticoagulation Trial Study Group.. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.. N Engl J Med 1995; 332: 1661-5.
• 24 Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and the risk of future venous thromboembolism.. Circulation 1997; 95: 1777-82.
• 25 Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia.. Am J Clin Nutr 1993; 57: 47-53.
• 26 Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency: the importance of adequate vitamin intake.. JAMA 1993; 270: 2726-7.
• 27 Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.. JAMA 1993; 270: 2693-8.